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Failure of Glycine-Arginine-α-Ketoisocaproic Acid
to Improve High-Intensity Exercise Performance 
in Trained Cyclists
Lukas Beis, Yaser Mohammad, Chris Easton, and Yannis P. Pitsiladis
Oral supplementation with glycine-arginine-α-ketoisocaproic acid (GAKIC) has previously been shown to 
improve exhaustive high-intensity exercise performance. There are no controlled studies involving GAKIC 
supplementation in well-trained subjects. The aim of the current study was to examine the effects of GAKIC 
supplementation on fatigue during high-intensity, repeated cycle sprints in trained cyclists. After at least 2 
familiarization trials, 10 well-trained male cyclists completed 2 supramaximal sprint tests each involving 10 
sprints of 10 s separated by 50-s rest intervals on an electrically braked cycle ergometer. Subjects ingested 
11.2 g of GAKIC or placebo (Pl) during a period of 45 min before the 2 experimental trials, administered in 
a randomized and double-blind fashion. Peak power declined from the 1st sprint (M ± SD; Pl 1,332 ± 307 
W, GAKIC 1,367 ± 342 W) to the 10th sprint (Pl 1,091 ± 229 W, GAKIC 1,061 ± 272 W) and did not differ 
between conditions (p = .88). Mean power declined from the 1st sprint (Pl 892 ± 151 W, GAKIC 892 ± 153 
W) to the 10th sprint (Pl 766 ± 120 W, GAKIC 752 ± 138 W) and did not differ between conditions (p = .96). 
The fatigue index remained at ~38% throughout the series of sprints and did not differ between conditions 
(p = .99). Heart rate and ratings of perceived exertion increased from the 1st sprint to the 10th sprint and did 
not differ between conditions (p = .11 and p = .83, respectively). In contrast to previous studies in untrained 
individuals, these results suggest that GAKIC has no ergogenic effect on repeated bouts of high-intensity 
exercise in trained individuals.
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The effects of amino acid supplementation on 
physical performance have been widely investigated, 
with some studies showing positive effects on strength 
(Crowe, Weatherson, & Bowden, 2006; Schena, Guer-
rini, Tregnaghi, & Kayser, 1992) and endurance perfor-
mance (Blomstrand, Hassmen, Ekblom, & Newsholme, 
1991), whereas other studies reported no ergogenic 
effect (Madsen, MacLean, Kiens, & Christensen, 1996; 
Pitkanen et al., 2003; van Hall, Raaymakers, Saris, & 
Wagenmakers, 1995). Despite conflicting results, amino 
acid supplementation among athletes is widespread 
(Ahrendt, 2001; Maughan, King, & Lea, 2004) in their 
belief that exercise performance will be enhanced. Two 
studies have examined the effects of a specific combi-
nation of amino acids, namely glycine, arginine, and 
α-ketoisocaproic acid (a breakdown product of leucine; 
GAKIC), on human performance during high-intensity 
short-duration exercise (Buford & Koch, 2004; Stevens, 
Godfrey, Kaminski, & Braith, 2000). In the first study, 
Stevens et al. found that GAKIC supplementation 
increased muscle torque and work sustained during 
intense acute anaerobic dynamic exercise and increased 
overall muscle performance by delaying muscle fatigue 
during the early phases of anaerobic dynamic exercise. 
In a subsequent study, Buford and Koch appeared to 
support the previous findings by reporting that GAKIC 
supplementation attenuated the decline in mean power 
output during repeated cycling sprints. Both studies 
employed untrained individuals as subjects. Although 
these are the only two studies to have examined the 
effects of GAKIC on exercise performance, both reported 
ergogenic effects yet neither seems to provide a clear 
mechanism by which the components of GAKIC act 
(individually or synergistically). The amino acids making 
up GAKIC appear to be active in the metabolic pathways 
associated with the biosynthesis of creatine, protein, 
and nitric oxide (Campbell, La Bounty, & Roberts, 
2004; Minuskin, Lavine, Ulman, & Fisher, 1981; Nair, 
Schwartz, & Welle, 1992). The effects of GAKIC may be 
to stabilize muscle pH or attenuate the rise in ammonia 
concentration (Greenstein, Birnbaum, Gullino, Otey, & 
Winitz, 1956) released from the purine nucleotide cycle 
(Meyer & Terjung, 1979;  Terjung, Dudley, & Meyer, 
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1985), possibly through  alterations in the enzymatic 
pathways of nitrogen metabolism (Jeevanandam, Ali, 
Holaday, Weis, & Petersen, 1993; Sitren & Fisher, 1977). 
As such, GAKIC could enhance high-intensity exercise 
performance, because ammonia accumulation has been 
implicated in fatigue (Wilkinson, Smeeton, & Watt, 
2010). GAKIC is marketed as a muscle-fatigue-toxin 
neutralizer (http://www.muscletech.com).
Although previous research indicates that GAKIC 
supplementation improves high-intensity exercise per-
formance (Buford & Koch, 2004; Stevens et al., 2000), 
the paucity of data warrants further investigation. Fur-
thermore, both previous studies (Buford & Koch, 2004; 
Stevens et al., 2000) used untrained subjects and failed 
to incorporate more than one baseline trial, leaving the 
reliability of the data open to question. The subjects in 
Buford and Koch’s study completed a modified  Wingate 
test consisting of five sprints of 10 s. Although there 
were no statistical differences in peak power output after 
GAKIC supplementation, an increased power output was 
reported in the last of the five sprints. Conceivably, had 
the experiment been continued to include further sprints, 
an attenuation in the decline in peak power output may 
have been observed after GAKIC supplementation. 
Therefore, the aim of this study was to investigate the 
effects of GAKIC on fatigue during a series of 10 sprints 
in trained cyclists using an experimental design nearly 
identical to that in Buford and Koch’s study. We hypoth-
esized that GAKIC supplementation would enhance peak 
power output and attenuate the decline in power output 




Ten trained male cyclists (age 33 ± 6 years, weight 72.4 
± 8.9 kg, height 176 ± 1 cm) gave their written informed 
consent to take part in the current study, which was 
approved by the local ethics committee and performed 
according to the code of ethics of the World Medical 
Association (Declaration of Helsinki). The sample size 
of the study was in accordance with the subject num-
bers used in the two previous studies involving GAKIC 
(Buford & Koch 2004; Stevens et al., 2000), as well as 
most previous relevant studies (see Hopkins, Schabort, & 
Hawley, 2001, for review). Subjects were in good health 
at the time of testing, trained almost daily, and partici-
pated regularly in local and national races.
All subjects completed two performance trials con-
sisting of 10 repeated supramaximal sprints. All tests were 
conducted on an electronically braked cycle ergometer 
(Lode Excalibur, Lode BV, Groningen, The Netherlands) 
at standard room temperature (19–21 °C) with 1 week 
separating the trials. Before these performance trials, 
familiarization trials were completed until the variability 
of peak power output was within a 5% difference between 
the two consecutive trials. No subject had to complete a 
third familiarization trial to achieve less than 5% vari-
ability, in line with our previous experience with trained 
cyclists. Subsequently, all subjects completed two per-
formance trials before which they ingested either GAKIC 
or placebo in a double-blinded crossover fashion and in 
accordance with previous studies (Buford & Koch, 2004; 
Stevens et al., 2000).
Experimental Procedures
Subjects reported to the laboratory on the day of test-
ing after a 3-hr fast and having refrained from alcohol 
and strenuous exercise the day before. On arrival at the 
laboratory, body mass (Avery Weight-Tronix 3302, ABN, 
Birmingham, UK) and height (Invicta Plastics Ltd., 
Leicester, UK) were measured. In addition, a heart-rate 
monitor (Polar Sports Tester, Polar Electro Oy, Kempele, 
Finland) was attached before each test. Subjects were 
also required to complete a 24-hr dietary record and 
reproduce this diet the day before each trial in an attempt 
to standardize the diet in terms of total energy intake, 
macronutrient intake, and quantity of specific amino acids 
(glycine, arginine, and leucine).
Experimental Design
Each subject ingested either 11.2 g of commercially 
available GAKIC (2.0 g glycine, 6.0 g L-arginine mono-
hydrochloride, 3.2 g α-ketoisocaproic acid calcium salt; 
Iovate Health Sciences Research Inc., Mississauga, ON, 
Canada) or placebo (9.46 g sucrose, 3.2 g calcium car-
bonate) before the experimental performance trials. No 
attempt was made to verify the presence of the active 
ingredients. Supplements were dissolved in 450 ml of 
sugar-free fruit juice, and subjects were required to wear 
a nose clip to prevent differentiating between beverages, 
because GAKIC has a distinguishable and fairly unpleas-
ant odor. It was confirmed via a simple discussion at 
the end of each experiment that subjects were not able 
to identify any differences between the treatments. The 
supplement was divided into three equal aliquots of 150 
ml and ingested 45, 30, and 10 min before exercise. 
Timing of ingestion and supplementation dose were in 
line with those used in the two previous studies (Buford 
& Koch, 2004; Stevens et al., 2000). After ingestion 
of the third and final beverage, subjects commenced a 
warm-up consisting of 5 min of cycling at 100–150 W, 
followed by a familiarization sprint of 5 s. The warm-up 
also consisted of stretching exercises depending on each 
individual. Subsequently, subjects performed a series of 
10 maximal-effort 10-s sprints, separated by 50-s rest 
intervals. Each sprint was a modified 10-s Wingate test 
performed using a resistance of 0.8 N/kg. Power output 
was analyzed using standard computer software (Version 
1, Lode BV, Groningen, The Netherlands). This analysis 
enabled calculation of both 10-s mean power output (the 
average power output during each sprint) and 10-s peak 
power output (the highest power during each sprint). Fur-
thermore, the fatigue index was determined as follows: 
Fatigue index % = [(peak power – minimum power)/peak 
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power] × 100, where the minimum power is the lowest 
power output after the subject achieved peak power 
output. After the 10 sprints, subjects were instructed to 
continue pedaling for at least 6–7 min to allow recovery 
to occur. Heart rate (HR) was recorded (Polar Sports 
Tester, Polar Electro Oy, Kempele, Finland) and ratings 
of perceived exertion (RPE) determined using the Borg 
category scale (Borg, 1982) at the end of each sprint.
Data Analysis
All data are expressed as M ± SD. After a test for the 
normality of distribution, all repeated-measures data 
(i.e., peak power, mean power, minimum power, fatigue 
index, HR, and RPE) were compared between the two 
treatments using a two-way repeated-measures analysis 
of variance. Other comparisons (i.e., total energy and 
macronutrients) were made using Student’s paired t test. 
Statistical significance was set at p < .05. All statistical 
analysis was completed using the software package SPSS, 
version 11.0 (SPSS, Inc., Chicago, IL).
Results
Generally, all subjects tolerated the supplementation 
protocol well, with no reports of gastrointestinal distress. 
There were no significant differences in either macro-
nutrient or micronutrient intake before either GAKIC 
or placebo trials. Detailed diet analysis is presented 
in Table 1. No significant differences were observed 
between GAKIC and placebo treatments in any of the 
measured performance variables. Peak power (Figure 1) 
declined from the first sprint (placebo 1,332 ± 307 W, 
GAKIC 1,367 ± 342 W) to the 10th sprint (placebo 
1,091 ± 229 W, GAKIC 1,061 ± 272 W) and did not differ 
significantly between conditions (p = .88). Mean power 
(Figure 2) declined from the first sprint (placebo 892 ± 
151 W, GAKIC 892 ± 153 W) to the 10th sprint (placebo 
766 ± 120 W, GAKIC 752 ± 138 W) and did not differ 
between conditions (p = .96); the average coefficients of 
variation for the 10 sprints taking into account both trials 
were 2.1% and 2.2% for peak and mean power output, 
respectively (calculated as indicated in Hopkins et al., 
2001). In general, the fatigue index (Figure 3) remained 
at ~38% throughout the series of sprints and did not differ 
between conditions (p = .99).
RPE increased from the first sprint (placebo 13 ± 3, 
GAKIC 13 ± 3) to the 10th sprint (placebo 19 ± 1, GAKIC 
20 ± 1) and did not differ between treatments (p = .11). In 
addition, HR increased from the first (placebo 151 ± 10, 
GAKIC 152 ± 12 beats/min) to the 10th sprint (placebo 
166 ± 11, GAKIC 164 ± 12 beats/min) and did not differ 
between conditions (p = .83).
Discussion
The findings of the current study suggest that GAKIC 
supplementation does not have an ergogenic effect on 
muscle power output or attenuation of fatigue during 
Table 1 Comparison of Total Energy Intake, 
Macronutrients, and Specific Amino Acids 
(M ± SD)
Variable GAKIC Placebo p
Energy (kJ) 11,246 ± 3,084 10,629 ± 3,808 .46
Carbohydrates (g) 392 ± 110 406 ± 143 .71
Protein (g) 98 ± 38 90 ± 39 .26
Fat (g) 86 ± 44 66 ± 44 .60
Arginine (mg) 1,727 ± 1,158 1,400 ± 585 .34
Leucine (mg) 2,358 ± 1,755 2,496 ± 1,602 .81
Glycine (mg) 1,393 ± 925 1,360 ± 1,023 .93
Note. GAKIC = glycine-arginine-α-ketoisocaproic acid.
Figure 1 — Peak power outputs over 10 repeated cycling sprints with glycine-arginine-α-ketoisocaproic acid (Gakic) and placebo 
treatments (N = 10, M ± SD).
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repeated sprints in trained cyclists. These results are in 
contrast to our initial hypothesis developed from previ-
ous literature that suggested that supplementation with 
GAKIC would enhance peak power output and attenuate 
the decline in power output during repeated high-intensity 
sprints. In the current study, GAKIC had no effect on 
peak power, mean power, minimum power, or fatigue 
index. In addition, no differences were found in HR or 
RPE between the two experimental conditions.
The data reported in the current study contradict 
both previous performance studies in which GAKIC 
was found to attenuate the decline in power output, 
improve muscle performance (Buford & Koch, 2004), 
and delay muscle fatigue, resulting in improved total 
work (Stevens et al., 2000) during high-intensity exer-
cise. In the initial study, Stevens et al. demonstrated 
that GAKIC supplementation increased muscle force 
production by up to 28%, increased total muscle work 
by at least 12%, and improved overall performance 
compared with placebo. Stevens et al.’s high-intensity 
experimental protocol consisted of 35 maximal, iso-
kinetic repetitions of knee extensions at a rate of 90°/s. 
In the later study, Buford and Koch reported a significant 
difference in mean power output during high-intensity 
exercise consisting of five repeated sprints of 10 s on a 
cycle ergometer. On the other hand, a more recent study 
(Yarrow, Parr, White, Borsa, & Stevens, 2007) failed 
to find any ergogenic effect during moderate- or high-
intensity exercise when the KIC component of GAKIC 
was examined in isolation.
Figure 2 — Mean power outputs over 10 repeated cycling sprints with glycine-arginine-α-ketoisocaproic acid (Gakic) and placebo 
treatments (N = 10, M ± SD).
Figure 3 — Fatigue index over 10 repeated cycling sprints with glycine-arginine-α-ketoisocaproic acid (Gakic) and placebo treat-
ments (N = 10, M ± SD).
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In both previous studies (Buford & Koch, 2004; 
Stevens et al., 2000), it was hypothesized that the spe-
cific combination of amino and keto acids contained in 
GAKIC could work synergistically to improve high-
intensity exercise performance through their relevant 
metabolic pathways. In theory this hypothesis could be 
proposed because the individual components of GAKIC 
have been shown to contribute to the detoxification of 
ammonia (Greenstein et al., 1956; Meneguello, Men-
donca, Lancha, & Costa Rosa, 2003), which is released 
from the purine nucleotide cycle (Meyer & Terjung, 
1979; Terjung et al., 1985) during high-intensity exer-
cise or from the catabolism of protein and deamination 
of amino acids (Sitren & Fisher, 1977; van Hall, van 
der Vusse, Soderlund, & Wagenmakers, 1995). The 
detoxification of ammonia could theoretically enhance 
high-intensity exercise performance because ammonia 
accumulation has been shown to be linked to muscle 
fatigue (Wilkinson et al., 2010), although the precise 
mechanisms remain to be determined. However, when 
the effect of each GAKIC component on exercise per-
formance was examined (Bower et al., 1995; Daly et al., 
1988; Jeevanandam et al., 1993; Nair et al., 1992; Wei-
mann et al., 1998), there was little evidence to support 
an ergogenic effect.
Arginine appears to be essential for human metabo-
lism only under specific circumstances such us burns, 
trauma, cancer (Bower et al., 1995; Daly et al., 1988; 
Weimann et al., 1998), and other conditions of rapid 
growth, apparently via the production of a number of 
hormones such as growth hormone (Besset, Bonardet, 
Rondouin, Descomps, & Passouant, 1982). However, 
most studies using a variety of doses of L-arginine have 
failed to show any effect on altering nitric oxide produc-
tion (Liu et al., 2009), influencing hormone levels (e.g., 
growth hormone), or indeed exercise performance (Liu 
et al., 2009; Marcell et al., 1999; McConell, Huynh, Lee-
Young, Canny, & Wadley, 2006). In addition, large doses 
of arginine have been shown to cause gastrointestinal 
discomfort (unpublished data cited in Wagenmakers, 
1999). On the other hand, glycine has an active role in 
the formation of creatine phosphate (as one of the three 
amino acids involved in synthesis of creatine), which 
is the main source of energy during intense exercise 
such as employed in the current study. The synthesis 
of creatine from arginine and glycine depends on the 
formation of guanidinoacetate, which is formed by the 
enzyme arginine:glycine amino-transferase (AGAT; 
Walker, 1979). Excess creatine leads to down-regulation 
of AGAT and in doing so inhibits the formation of gua-
nidinoacetate (Stead, Au, Jacobs, Brosnan, & Brosnan, 
2001). Therefore, the rate-limiting step in the formation 
of creatine is not the concentration of arginine but the 
formation of guanidinoacetate from AGAT (Campbell 
et al., 2004). Consequently, supplementation with argi-
nine would not necessarily lead to a higher intramuscular 
creatine concentration. Previous studies involving KIC or 
leucine supplementation (individually or in conjunction 
with other amino acids such as the branched-chain amino 
acids) have also failed to find any effect on aerobic or 
anaerobic performance (Madsen et al., 1996; Pitkanen 
et al., 2003; van Hall, Raaymakers, et al., 1995; Yarrow 
et al., 2007). Leucine supplementation seems ineffec-
tive in altering nitrogen balance (Sandstedt, Jorfeldt, & 
Larsson, 1992) or protein degradation (Sandstedt, Jor-
feldt, & Larsson, 1992) or reducing the concentration of 
ammonia (MacLean, Graham, & Saltin, 1996; Madsen 
et al., 1996). Therefore, the underlying mechanism 
behind the performance-enhancing effects of GAKIC 
supplementation reported in the two aforementioned 
studies (Buford & Koch, 2004; Stevens et al., 2000) 
remains elusive.
Alternatively, and possibly most likely, the findings 
in the previous studies (Buford & Koch, 2004; Stevens 
et al., 2000) could be a result of the experimental design 
and methodology employed. For example, Stevens et al., 
using untrained subjects, failed to include baseline trials 
to establish the repeatability of the performance trials. 
It remains a distinct possibility that the differences in 
power output observed in the previous studies (Buford 
& Koch, 2004; Stevens et al., 2000) were caused by a 
lack of reliability between performance trials, especially 
since untrained subjects were used (Hopkins et al., 2001; 
Coleman, Wiles, Nunn, & Smith, 2005; Hebestreit, 
Dunstheimer, Staschen, & Strassburg, 1999). Although 
subjects’ maximal oxygen uptake was not measured in 
the current study, peak power output is an established 
good predictor of maximal oxygen uptake (Hawley & 
Noakes, 1992). Peak power output of the first sprint in 
the current study was 1,297 ± 263 W for the placebo 
trial and 1,353 ± 283 W for the GAKIC trial, compared 
with approximately 750 W in the study by Buford and 
Koch, reflecting the clear difference in training status 
of the subjects between studies. Therefore, there are 
several possible explanations for the difference in reli-
ability between athletes (used in the current study) and 
nonathletes (used in the previous studies by Stevens et 
al. [2000] and Buford & Koch [2004]). First, the frequent 
exposure to high-intensity exercise on an almost daily 
basis may eliminate performance variability (Hopkins 
et al., 2001). Second, physical conditioning during the 
course of a study should not change to the same extent 
in trained and nontrained individuals. Third, and possi-
bly the most likely explanation, is the custom-to-detail 
approach typically associated with trained cyclists (e.g., 
using customized cycling shoes and pedals, fixed cycling 
position). Finally, assuming a constant random error 
contributed by equipment or examiners, this error will 
have less impact on overall outcome when expressed 
as a percentage of the higher power output of trained 
individuals (Hopkins et al., 2001). In the current study, 
variability in performance trials between familiariza-
tion trials was small (i.e., <5%), as would be expected 
from subjects who are well accustomed to the exercise 
protocols employed (Coleman et al., 2005; Hebestreit 
et al., 1999; Hopkins et al., 2001). The more stringent 
methodology used in the current study ensured that all 
possible confounding factors were minimized.
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Conclusion
The data from the current study do not support the find-
ings of previous studies (Buford & Koch, 2004; Stevens 
et al., 2000) that GAKIC supplementation will enhance 
high-intensity exercise performance. After we controlled 
for all possible confounding factors that could have 
adversely affected the results, GAKIC supplementation 
had no effect on peak power, mean power, or fatigue 
index. On the basis of this finding and those of previous 
studies involving the individual components of GAKIC, 
there appears to be little evidence to support the ergo-
genic effects of GAKIC during high-intensity exercise 
performance in well-trained subjects.
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